James Engelhart, Chief Financial Officer at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 70,000 shares at $103.85 ($7.2M) on 2021-12-10, disclosed to the SEC on 2021-12-10.
Open-market sale of $7.2M BHVN by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $102.01 | 10,131 | $1.0M | 14.4% |
| 2 | $102.01 | 10,131 | $1.0M | 14.4% |
| 3 | $102.70 | 23,487 | $2.4M | 33.6% |
| 4 | $102.70 | 23,487 | $2.4M | 33.6% |
| 5 | $103.85 | 1,382 | $144K | 2.0% |
| 6 | $103.85 | 1,382 |
| $144K |
| 2.0% |
| Total | $102.55 avg | 70,000 | $7.2M | 100% |
| Filing → |
| BHVN | SELL | 2018-05-30 | $175K | — | Filing → |
| BHVN | SELL | 2018-05-09 | $69K | — | Filing → |
| BHVN | SELL | 2018-02-23 | $16K | — | Filing → |